NIAID Clinical Trials Update - Rare Diseases - ClinicalTrials.gov - ClinicalTrials.gov

NIAID Clinical Trials Update – Rare Diseases

NIAID recognizes Rare Disease Day, February 28, 2011, which was established to raise awareness of the impact these diseases have on patients’ lives and the importance of biomedical research to develop diagnostics and treatments. NIAID is seeking volunteers to participate in clinical trials on rare conditions. The following are selected trials with links to full study titles, descriptions, and locations:


► Investigational Treatment for Idiopathic CD4 Lymphocytopenia (NCT00839436) evaluates the safety and immune-boosting ability of interleukin 7 in patients with idiopathic CD4 lymphocytopenia (ICL).
· Who may be eligible? Individuals 18 years of age and older diagnosed with ICL.
full-text
Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells
(ICICLE) - Full Text View - ClinicalTrials.gov



► Reducing the Side Effects of Standard Treatment of Loa Loa Infection (NCT01111305) evaluates the experimental drug reslizumab in the treatment of Loa loa infection.
· Who may be eligible? Individuals 18 to 65 years of age who have lived in or traveled to Loa-endemic regions in central and western Africa for at least 1 month.

full-text:
A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection - Full Text View - ClinicalTrials.gov



► Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (NCT01086540) aims to determine if the drug rituximab has a beneficial effect on disease progression, with minimal toxicity, when compared to placebo in patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH).
· Who may be eligible? Individuals 18 to 70 years of age with SSc-PAH.

full-text:
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) - Full Text View - ClinicalTrials.gov




► Safety Trial of Fludase in Adults with Bronchiectasis (NCT01113034) evaluates whether the medication DAS181 is safe in people with well-controlled asthma or bronchiectasis.
· Who may be eligible? Individuals 18 to 65 years of age with a diagnosis of bronchiectasis based on CT scan findings within 12 months of study enrollment, less than 2 acute exacerbations in the last 12 months and none in the last 4 weeks, and who have had no change in treatment for chronic lung infection within the last 3 months.

full-text:
A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis - Full Text View - ClinicalTrials.gov



► Scleroderma: Cyclophosphamide or Transplantation (SCOT – NCT00114530) compares two ways of treating scleroderma. Find out more on the SCOT study Web site.
· Who may be eligible? Individuals 18 to 69 years of age with severe forms of scleroderma.

full-text:
Scleroderma: Cyclophosphamide or Transplantation (SCOT) - Full Text View - ClinicalTrials.gov